ok, here's a nifty one:
http://www.businessw...s/D8UJQIT81.htm
"In a note to clients, Piper Jaffray analyst Edward A. Tenthoff said in the second half of 2008 he expects the company to report positive midstage clinical data for experimental diabetes drug SRT-501. He also thinks several other factors will drive up the stock in 2008.
Among them, Sirtris will likely move its first new chemical entity targeting SIRT1 -- which has been shown to regulate parts of the cell responsible for producing energy -- into the clinic during the first half of 2008, the analyst said. He noted that this drug is up to 1,000 times more potent than SRT-501."
Can this analyst be trying to push Sirtris prices up? That last sentence appears to be news to me, maybe even to Sirtris?
I wonder where he got his information, I think he meant "Resveratrol" and not SRT501. But to tell your clients this info?
hmmm...
A
Piper Jaffray was one of the original underwriters.
Maybe Insiders are strating to sell some shares.
Shares are trading for $12 and some insiders paid half a cent to $1.86/share
read the SIRT IPO:
see page F26 and page F29
The Company recorded the value of those shares as general and administrative expense in 2004.
In February 2005, the Company hired a president and chief executive officer (the CEO). In connection with such hiring, the Company issued 380,952 shares of restricted common stock to the CEO at $0.005 per share, which was less than the fair value of $0.32 per share, determined by the Company's Board of Directors. The Company has the right to repurchase 304,762 of these shares for $0.005 per share. Such repurchase rights expire annually at a rate of 20% beginning on January 1, 2006. As of December 31, 2005 and 2006 and March 31, 2007, 304,762, 152,381 and 133,333 shares, respectively, were subject to repurchase by the Company. The Company recorded the intrinsic value of the unvested shares of $95 as deferred compensation in 2005, and was recognizing the amount ratably over the remaining vesting period. Upon the adoption of SFAS 123® in January 2006, the Company reclassified $73 of unamortized deferred compensation to additional paid-in capital. Stock-based compensation expense of $45, $24 $6, $6 and $75 was recorded in the years ended December 31, 2005 and 2006, the three month periods ended March 31, 2006 and 2007 and the period from March 25, 2004 (date of inception) to March 31, 2007 in connection with this restricted stock award.
________________
In August 2004, the Company issued 10,000,000 shares of Series A redeemable convertible preferred stock (Series A Preferred stock) at $0.50 per share for net proceeds of $4,920.
In November 2004, the Company issued 21,666,667 shares of Series A-1 redeemable convertible preferred stock (Series A-1 Preferred Stock) at $0.60 per share for net proceeds of $12,927.
In February and March 2005, the Company issued 33,750,000 shares of Series B redeemable convertible preferred stock (Series B Preferred Stock) at $0.80 per share for net proceeds of $26,860.
In March and April 2006, the Company issued 19,700,892 shares of Series C redeemable convertible preferred stock (Series C Preferred Stock) at $1.12 per share for net proceeds of $21,969.
In January and February 2007, the Company issued 21,389,880 shares of Series C-1 redeemable convertible preferred stock (Series C-1 Preferred Stock) at $1.68 per share for net proceeds of $35,890.
